Codexis, Inc. (Nasdaq:CDXS) announced today that collaborative research conducted by Merck and Codexis scientists to develop a highly efficient, enzyme-based production method for a key intermediate in the production of boceprevir has been recently published in the Journal of the American Chemical Society (JACS). Boceprevir is the active ingredient in Merck's VICTRELIS™ (boceprevir) capsules. “The Codexis technology has delivered solid results including the reduction in production costs for boceprevir,” said Peter Seufer-Wasserthal, Ph.D., Sr. Vice President, Codexis Pharmaceuticals. “This important peer-reviewed publication highlights our continued track record of success in developing innovative, cost effective, practical processes for commercial scale manufacture of therapeutic compounds.” The JACS publication describes the creation and characterization of a custom enzyme or biocatalyst that was capable of performing a key step in the synthesis of boceprevir. The new method increased chemical intermediate yield 150 percent over the previous process, and reduced raw material use by 60 percent, water use by 61 percent and overall process waste by 63 percent. Codexis used its proprietary CodeEvolver™ directed evolution technology to develop a custom enzyme that can be used in the commercial scale manufacturing of the boceprevir intermediate. "Incorporation of innovative environmentally sustainable means of manufacture is a key aspect of our research and development strategy," said Richard Tillyer, Ph.D., senior vice president Discovery and Preclinical Sciences, Merck Research Laboratories. "Enzymatic based methods can offer a biodegradable and renewable alternative to currently employed methods." To view the publication, please go to: http://pubs.acs.org/doi/pdf/10.1021/ja3010495About Codexis, Inc. Codexis, Inc. is a developer of industrial enzymes to enable the production of biofuels, biobased chemicals and pharmaceutical intermediates. Codexis' product lines include CodeXyme™ Cellulase Enzymes and CodeXol™ Detergent Alcohol. Partners and customers include global leaders such as Shell, Merck and Pfizer. For more information, see www.codexis.com.